Polymorphic forms of ST-246 and methods of preparation
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
1. A polymorph Form IV of 4-trifluoromethyl-N-(3,3 a,4,4a, 5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2θ of 6.97, 9.75, 11.21, 12.13, 13.54, 16.82, 18.17, 18.79, 19.69, 20.51, 23.31, 24.78, 27.24, 30.20, and 33.52 degrees.
2. A polymorph according to claim 1 that is at least about 70% free of other forms.
3. A polymorph according to claim 1 that is at least about 80% free of other forms.
4. A polymorph according to claim 1 that is at least about 90% free of other forms.
5. A polymorph according claim 1 that is at least about 95% free of other forms.
6. A polymorph according claim 1 that is at least about 99% free of other forms.
7. A pharmaceutical composition comprising the polymorph of claim 1 and further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of carriers, excipients, diluents, additives, fillers, lubricants and binders.
8. The pharmaceutical composition of claim 7 , wherein the composition is formulated for oral administration.
9. A pharmaceutical composition comprising the polymorph of claim 1 and further comprising hydroxypropyl methylcellulose.